Critical caring

It takes a plethora of products and people to provide patients premium protection.

Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change in how healthcare is delivered. Technologies have emerged to support today’s data-driven, value-based care environment. The intensive care unit (ICU), which accounts for 13 percent of hospitals’ costs,1 is a target area for new interventions that can help clinicians detect issues sooner, intervene more effectively and reduce length of stay.

HPN talks with the experts about trends in critical care medicine and new products designed to support healthcare’s changing needs.

Early detection of complications

The combination of acute renal failure and sepsis is associated with a 70 percent mortality rate,2therefore early detection and management of these complications is key to saving lives. But invasive monitoring for these conditions can require that patients be sedated, which can increase the risk for further complications.3 To overcome these challenges, manufacturers like Deltex Medical have developed advanced non-invasive monitoring technologies that enable clinicians to identify the warning signs sooner.

“There are two main trends impacting our haemodynamic monitoring system offering to ICUs,” said Deltex Medical Managing Director Andy Mears. “Firstly there is a move towards keeping patients awake rather than sedated. This is driving demand for non-invasive haemodynamic monitoring. Secondly there is growing demand for monitors that help the early identification and treatment of sepsis and acute kidney injury (AKI). This is driving demand for high end technologies that can be relied upon to detect small ‘early warning’ changes and then guide complex interventions involving both intravenous fluids and vasoactive drugs.”

Deltex recently introduced TrueVue Impedance (FDA 510K submitted) to its TrueVue monitoring platform: this is a non-invasive, state of the art High Definition Impedance Cardiography suitable for use on awake patients even when they are moving about. In March 2018, Deltex also introduced its new TrueVue Loops display, which is the first technology to display both central blood flow and pressure beat-to-beat in real time giving clinicians a complete picture of each of the three components of haemodynamics: flow, pressure and resistance. According to the company, this is expected to be a major advance in the prevention, early detection and safe treatment of both sepsis and AKI.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    FEDORA Study “Take-Homes” for clinicians

    Clinician-led disseminator of medical news, TopMedTalk has reviewed the landmark FEDORA study into Goal-Directed Haemodynamic Therapy (GDHT). Reinforcing the conclusions from meta-analysis of 70 other studies, FEDORA supports the use of Oesophageal Doppler to derive clinical parameters that